May 14, 2008 A chemical reaction in genes that control breast cancer provides a molecular clock that could one day help researchers more accurately determine a woman's risk for developing breast cancer and provide a new approach for treatment, UT
Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer, according to a Phase II clinical
IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced that researchers from the University of Texas MD Anderson Cancer Center (MDACC, Houston, TX) will present the results
Chicago -- The interaction of sex, age and ethnicity has a significant impact on overall survival in metastatic colorectal cancer (MCRC) patients, a study led by researchers at the University of Southern California (USC) and USC/Norris Comprehensive Cancer Center suggests.
According to an article in the June issue of Radiology, researchers at The George Washington University Medical Center in Washington, D.C. have shown that Breast-Specific Gamma Imaging (BSGI) is highly sensitive in detecting the presence of cancer. The researchers determined
Celator Pharmaceuticals reported positive results from its CPX-1 Phase 2 clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company's proprietary CombiPlex(TM) technology. The results were presented in a
NEW YORK -- Prostate cancer is the second leading cause of death among American males, but when caught early, prostate cancer has a 90% cure rate. According to Dr. David Samadi, Chief, Division of Robotics and Minimally Invasive Surgery, Department
WILMINGTON, Mass. -- Sirtex, a leading developer of targeted and innovative cancer therapies, will exhibit its SIR-Spheres microspheres technology at the 2008 Society of Nuclear Medicine (SNM) Annual Meeting. The meeting, to be held June 14-18 at the Convention Center
Poniard Pharmaceuticals, Inc. (NASDAQ:PARD), a biopharmaceutical company focused on oncology, announced positive preliminary results from its ongoing randomized Phase 2 clinical trial in patients with metastatic colorectal cancer (CRC) and updated results from an ongoing Phase 1 CRC trial. Preliminary
Mesothelioma is a deadly condition. If you or a family member is diagnosed with mesothelioma then find information here. Those suffering from mesothelioma, should consider hiring a lawyer.A San Francisco jury has awarded a $20 million damages verdict to a
On July 1, 2008, a husband and wife in Texas filed an asbestos related lawsuit against 16 companies. The lawsuit claims that the companies conspired to mine and sell asbestos products in addition to suppressing the information from employees. The
